What the label lists and what reports show

Dexamethasone and neomycin and polymyxin b side effects

Dexamethasone and neomycin and polymyxin b's FDA label lists its adverse reactions in its own words. FAERS holds 1,077 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is eye pain (90 reports).

Generic listed

Check it at the source: the dexamethasone and neomycin and polymyxin b FDA label on DailyMed (effective October 31, 2024, Sandoz Inc); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions
Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the steroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid. …

Source: FDA drug label, Sandoz Inc, effective October 31, 2024 (SPL set 7f2e3c46-9f39-45e7-99a9-64cc4f6f649d), via openFDA; the full label on DailyMed

What do FAERS reports show?

1,077 reports list dexamethasone and neomycin and polymyxin b among the medicines taken, each a report of something that happened, not proof the medicine caused it; 50 are coded as a death and 224 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 21 reactions below, 3 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

Eye Pain90
Eye Irritation79
Vision Blurred70
Ocular Hyperaemia60
Off Label Use (a use or a product term, not a reaction)57
Pain52
Visual Impairment52
Drug Ineffective (a use or a product term, not a reaction)47
Headache (named in the label)43
Fatigue42
Dyspnoea38
Condition Aggravated (a use or a product term, not a reaction)37
Anxiety35
Intraocular Pressure Increased35
Nausea35
Dizziness33
Lacrimation Increased32
Ulcerative Keratitis (named in the label)32
Diarrhoea31
Hypersensitivity (named in the label)31
Visual Acuity Reduced31
Drug Hypersensitivity30
Drug Interaction (a use or a product term, not a reaction)29
Dry Eye29
Eye Swelling28

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Dexamethasone and neomycin and polymyxin b: the full record: label, generics, price, shortages, recalls
Report a side effect to the FDA: MedWatch
Side effects hub: the most reported medicines and reactions